Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some?
Lancet
.
2023 Oct 21;402(10411):1394-1395.
doi: 10.1016/S0140-6736(23)01783-X.
Epub 2023 Aug 23.
Authors
Sibylle Loibl
1
,
Johannes Holtschmidt
2
Affiliations
1
German Breast Group, Forschungs, Germany; Neu-Isenburg and Centre for Haematology and Oncology Bethanien, Frankfurt 63263, Germany. Electronic address: sibylle.loibl@gbg.de.
2
German Breast Group, Forschungs, Germany.
PMID:
37633307
DOI:
10.1016/S0140-6736(23)01783-X
No abstract available